


CURRICULUM VITAE

Name: Teh-Ia Huo, MD

Office Address: Department of Medical Research,
Taipei Veterans General Hospital, Taipei, Taiwan

E-mail: tihuo@vghtpe.gov.tw; huotehyi@gmail.com



Hospital Appointment:

Attending Physician, Division of Gastroenterology, Department of Medicine,
Taipei Veterans General Hospital, Taiwan, 1997 to date
Chief, Div. of Basic Science, Department of Medical Research, Taipei Veterans
General Hospital, Taiwan, 2019 to date

Academic Appointment:

Professor:
Institute of Pharmacology, National Yang-Ming University School of Medicine,
Taipei, Taiwan
2006 to date

Distinguished Professor
National Yang-Ming University School of Medicine, Taipei, Taiwan
2017 to date

Publications since 2010: (* indicates corresponding author)

Refereed paper included in Science Citation Index:

1. Chia-Yang Hsu, Yi-Hsiang Huang, Chien-Wei Su, Han-Chieh Lin, Jen-Huey Chiang, Pui-Ching Lee, Fa-Yauh Lee, Teh-Ia Huo*, Shou-Dong Lee. Renal failure in patients with hepatocellular carcinoma and ascites undergoing transarterial chemoembolization. *Liver Int* 2010;30:77-84. (*with an editorial*) (NSC 96-2314-B-010-023-MY2, VGH V98C1-132).
2. Teh-Ia Huo*, Chia-Yang Hsu, Yi-Hsiang Huang, Cheng-Yuan Hsia, Han-Chieh Lin, Pui-Ching Lee, Che-Chuan Loong, Jen-Huey Chiang, Yi-You Chiou, Shou-Dong Lee. Diabetes mellitus as an independent prognostic predictor and its association with renal dysfunction in patients with hepatocellular carcinoma. *Liver Int* 2010;30:198-207.

(NSC 96-2314-B-010-023-MY2, VGH V98C1-132)

3. Chia-Yang Hsu, Han-Chieh Lin, Yi-Hsiang Huang, Chien-Wei Su, Fa-Yauh Lee, Teh-Ia Huo*, Pui-Ching Lee, Jing-Yi Lee, Shou-Dong Lee. Comparison of the model for end-stage liver disease (MELD), MELD-Na and MELDNa for outcome prediction in patients with acute decompensated hepatitis. *Dig Liver Dis* 2010;42:137-42. (NSC 96-2314-B-010-023-MY2, VGH V98C1-132)
4. Teh-Ia Huo*, Chia-Yang Hsu, Han-Chieh Lin, Pui-Ching Lee, Jing-Yi Lee, Fa-Yauh Lee, Ming-Chih Hou, Shou-Dong Lee. Selecting an optimal cutoff value for creatinine in the model for end-stage liver disease equation. *Clin Transplant* 2010;24:157-63. (NSC 96-2314-B-010-023-MY2, VGH V98C1-132)
5. Chia-Yang Hsu, Yi-Hsiang Huang, Cheng-Yuan Hsia, Chien-Wei Su, Han-Chieh Lin, Pui-Ching Lee, Che-Chuan Loong, Jen-Huei Chiang, Teh-Ia Huo*, Shou-Dong Lee. Selecting an optimal staging system for hepatocellular carcinoma: comparison of 5 currently used prognostic models. *Cancer* 2010;116:3006-14. (NSC 96-2314-B-010-023-MY2, VGH V98C1-132)
6. Chia-Yang Hsu, Yi-Hsiang Huang, Cheng-Yuan Hsia, Chien-Wei Su, Han-Chieh Lin, Che-Chuan Loong, Yi-You Chiou, Jen-Huey Chiang, Pui-Ching Lee, Teh-Ia Huo*, Shou-Dong Lee. A new prognostic model for hepatocellular carcinoma based on total tumor volume: the Taipei Integrated Scoring system. *J Hepatol* 2010;53:108-17. (*with an editorial*)
7. Chia-Yang Hsu, Yi-Hsiang Huang, Jen-Huey Chiang, Han-Chieh Lin, Chien-Wei Su, Pui-Ching Lee, Fa-Yauh Lee, Teh-Ia Huo*, Shou-Dong Lee. Transarterial chemoembolization in patients with hepatocellular carcinoma and renal insufficiency. *J Clin Gastroenterol* 2010; 44: e171-e177. (NSC 96-2314-B-010-023-MY2, VGH V98C1-132)
8. Teh-Ia Huo*, Chia-Yang Hsu, Yi-Hsiang Huang, Chien-Wei Su, Han-Chieh Lin, Rheun-Chuan Lee, Yi-You Chiou, Jen-Huey Chiang, Pui-Ching Lee, Shou-Dong Lee. Prognostic prediction across a gradient of total tumor volume in patients with hepatocellular carcinoma undergoing locoregional therapy. *BMC Gastroenterol* 2010;10:146.
9. Teh-Ia Huo*. The global spread of 2009 H1N1 influenza: a false pandemic? *J Chin*

- Med Assoc 2010;73:60-1.
10. Teh-Ia Huo*. The first case of multidrug-resistant NDM-1-harboring *Enterobacteriaceae* in Taiwan: Here comes the superbacteria! J Chin Med Assoc 2010;73:557-8.
 11. Lee IC, Chan CC, Huang YH*, Huo TI*, Chu CJ, Lai CR, Lee PC, Su CW, Hung HH, Wu JC, Lin HC, Lee SD. Comparative analysis of noninvasive models to predict early liver fibrosis in hepatitis B e antigen-negative chronic hepatitis B. J Clin Gastroenterol 2011;45:278-85.
 12. Chia-Yang Hsu, Yi-Hsiang Huang, Chien-Wei Su, Han-Chieh Lin, Yi-You Chiou, Rheun-Chuan Lee, Jen-Huey Chiang, Teh-Ia Huo*, Fa-Yauh Lee, Shou-Dong Lee. Comparison of radiofrequency ablation and transarterial chemoembolization for hepatocellular carcinoma within the Milan criteria: a propensity score analysis. Liver Transpl 2011;17:556-66.
 13. I-Fang Hsin, Chia-Yang Hsu, Hui-Chun Huang, Yi-Hsiang Huang, Han-Chieh Lin, Rheun-Chuan Lee, Jen-Huey Chiang, Fa-Yauh Lee, Teh-Ia Huo*, Shou-Dong Lee. Liver failure after transarterial chemoembolization for patients with hepatocellular carcinoma and ascites: incidence, risk factors and prognostic prediction. J Clin Gastroenterol 2011;45:556-62.
 14. Hsin-Yang Li, Yueh Chien, Yi-Jen Chen, Szu-Fu Chen, Yuh-Lih Chang, Chih-Hung Chiang, Shaw-Yeu Jeng, Chia-Ming Chang, Mong-Lien Wang, Liang-Kung Chen, Shuen-Iu Hung, Teh-Ia Huo*, Shou-Dong Lee, Shih-Hwa Chiou*. Reprogramming induced pluripotent stem cells in the absence of c-Myc for differentiation into hepatocyte-like cells. Biomaterials 2011;32:5994-6005.
 15. Ya-Ju Tsai, Chia-Yang Hsu, Yi-Hsiang Huang, Chien-Wei Su, Han-Chieh Lin, Rheun-Chuan Lee, Jen-Huey Chiang, Teh-Ia Huo*, Shou-Dong Lee. Early identification of poor responders to transarterial chemoembolization for hepatocellular carcinoma. Hepatol Int 2011;5:975-84.
 16. Chia-Yang Hsu, Cheng-Yuan Hsia, Yi-Hsiang Huang, Chien-Wei Su, Han-Chieh Lin, Jih-Tung Pai, Che-Chuan Loong, Yi-You Chiou, Rheun-Chuan Lee, Fa-Yauh Lee, Teh-Ia Huo*, Shou-Dong Lee. Comparison of surgical resection and transarterial chemoembolization for hepatocellular carcinoma beyond the Milan criteria: a

- propensity score analysis. *Ann Surg Oncol* 2012;19:842-9.
17. Chia-Yang Hsu, Cheng-Yuan Hsia, Yi-Hsiang Huang, Chien-Wei Su, Han-Chieh Lin, Yi-You Chiou, Rheun-Chuan Lee, Fa-Yauh Lee, Teh-Ia Huo*, Shou-Dong Lee. Differential prognostic impact of renal insufficiency on patients with hepatocellular carcinoma: a propensity score analysis and staging strategy. *J Gastroenterol Hepatol* 2012;27:690-9.
 18. Hua-Ming Chang, Yi-Wen Liao, Chih-Hung Chiang, Yi-Jen Chen, Ying-Hsiu Lai, Yuh-Lih Chang, Hen-Li Chen, Shaw-Yeu Jeng, Jung-Hung Hsieh, Chi-Hsien Peng, Hsin-Yang Li, Yueh Chien*, Szu-Yu Chen, Liang-Kung Chen, Teh-Ia Huo*. Improvement of carbon tetrachloride-induced acute hepatic failure by transplantation of induced pluripotent stem cells without reprogramming factor c-Myc. *Int J Mol Sci* 2012;13:3598-617.
 19. Yun-Hsuan Lee, Chia-Yang Hsu, Cheng-Yuan Hsia, Yi-Hsiang Huang, Chien-Wei Su, Han-Chieh Lin, Yi-You Chiou, Teh-Ia Huo*. A prognostic model for patients with hepatocellular carcinoma within the Milan criteria undergoing non-transplant therapies, based on 1106 patients. *Aliment Pharmacol Ther* 2012;36:551-9.
 20. Yun-Hsuan Lee, Chia-Yang Hsu, Yi-Hsiang Huang, Chien-Wei Su, Han-Chieh Lin, Che-Chuan Loong, Yi-You Chiou, Teh-Ia Huo*. Defining the severity of liver dysfunction in patients with hepatocellular carcinoma by the model for end-stage liver disease-derived systems. *Dig Liver Dis* 2012;44:868-74.
 21. Yun-Hsuan Lee, Chia-Yang Hsu, Yi-Hsiang Huang, Chien-Wei Su, Han-Chieh Lin, Rheun-Chuan Lee, Yi-You Chiou, Teh-Ia Huo*, Shou-Dong Lee. Selecting a prognostic renal surrogate for patients with hepatocellular carcinoma undergoing transarterial chemoembolization. *J Gastroenterol Hepatol* 2012;27:1581-8.
 22. Chia-Yang Hsu, Yun-Hsuan Lee, Cheng-Yuan Hsia, Yi-Hsiang Huang, Chien-Wei Su, Han-Chieh Lin, Rheun-Chuan Lee, Yi-You Chiou, Fa-Yauh Lee, Teh-Ia Huo*. Performance status in patients with hepatocellular carcinoma: Determinants, prognostic impact and ability to improve the Barcelona Clinic Liver Cancer system. *Hepatology* 2013;57:112-9.
 23. Yun-Hsuan Lee, Chia-Yang Hsu, Cheng-Yuan Hsia, Yi-Hsiang Huang, Chien-Wei Su, Han-Chieh Lin, Rheun-Chuan Lee, Yi-You Chiou, Teh-Ia Huo*. Hepatocellular

- carcinoma in uremic patients: Is there evidence for an increased risk of mortality? *J Gastroenterol Hepatol* 2013;28:348-56.
24. Yun-Hsuan Lee, Chia-Yang Hsu, Yi-Hsiang Huang, Chien-Wei Su, Han-Chieh Lin, Cheng-Yuan Hsia, Teh-Ia Huo*. α -fetoprotein-to-total tumor volume ratio predicts post-operative tumor recurrence in hepatocellular carcinoma. *J Gastrointest Surg* 2013;17:730-8.
 25. Chia-Yang Hsu, Yun-Hsuan Lee, Yi-Hsiang Huang, Cheng-Yuan Hsia, Chien-Wei Su, Han-Chieh Lin, Rheun-Chuan Lee, Yi-You Chiou, Fa-Yauh Lee, Teh-Ia Huo*, Shou-Dong Lee. Ascites in patients with hepatocellular carcinoma: prevalence, associated factors, prognostic impact and staging strategy. *Hepatol Int* 2013;7:188-98.
 26. Yun-Hsuan Lee, Cheng-Yuan Hsia, Chia-Yang Hsu, Yi-Hsiang Huang, Han-Chieh Lin, Teh-Ia Huo*. Total tumor volume is a better marker of tumor burden in hepatocellular carcinoma defined by the Milan criteria. *World J Surg* 2013;37:1348-55.
 27. Chia-Yang Hsu, Yun-Hsuan Lee, Cheng-Yuan Hsia, Yi-Hsiang Huang, Chien-Wei Su, Han-Chieh Lin, Yi-You Chiou, Fa-Yauh Lee, Teh-Ia Huo*. Performance status enhances the selection of treatment for patients with hepatocellular carcinoma within the Milan criteria. *Ann Surg Oncol* 2013;20:2035-42.
 28. Yun-Hsuan Lee, Chia-Yang Hsu, Cheng-Yuan Hsia, Yi-Hsiang Huang, Chien-Wei Su, Yi-You Chiou, Han-Chieh Lin, Teh-Ia Huo*, Shou-Dong Lee. Alcoholism worsens the survival of patients with hepatitis B virus and C virus-related hepatocellular carcinoma. *Hepatol Int* 2013;7:645-54.
 29. Yun-Hsuan Lee, Chia-Yang Hsu, Teh-Ia Huo*. Assessing liver dysfunction in cirrhosis: Role of the model for end-stage liver disease and its derived systems. *J Chin Med Asso* 2013;76:419-24.
 30. Chia-Yang Hsu, Yun-Hsuan Lee, Po-Hong Liu, Cheng-Yuan Hsia, Yi-Hsiang Huang, Han-Chieh Lin, Yi-You Chiou, Fa-Yauh Lee, Teh-Ia Huo*. Decrypting cryptogenic hepatocellular carcinoma: Clinical manifestations, prognostic factors and long-term survival by propensity score model. *PLoS One* 2014;9: e89373.
 31. Po-Hong Liu, Yun-Hsuan Lee, Cheng-Yuan Hsia, Chia-Yang Hsu, Yi-Hsiang Huang,

- Yi-You Chiou, Han-Chieh Lin, Teh-Ia Huo*. Surgical resection versus transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombosis: a propensity score analysis. *Ann Surg Oncol* 2014;21:1825-33.
32. Yun-Hsuan Lee, Chia-Yang Hsu, Chen-Wei Chu, Po-Hong Liu, Cheng-Yuan Hsia, Yi-Hsiang Huang, Chien-Wei Su, Yi-You Chiou, Han-Chieh Lin, Teh-Ia Huo*. A new Child-Turcotte-Pugh class 0 for patients with hepatocellular carcinoma: determinants, prognostic impact and ability to improve the current staging systems. *PLoS One* 2014;9: e99115.
 33. Yun-Hsuan Lee, Chia-Yang Hsu, Yi-Hsiang Huang, Cheng-Yuan Hsia, Yi-You Chiou, Chien-Wei Su, Han-Chieh Lin, Teh-Ia Huo*. Vascular invasion in hepatocellular carcinoma: Prevalence, determinants and prognostic impact. *J Clin Gastroenterol* 2014;48:734-41.
 34. Po-Hong Liu, Yun-Hsuan Lee, Chia-Yang Hsu, Cheng-Yuan Hsia, Yi-Hsiang Huang, MD, Yi-You Chiou, Han-Chieh Lin, Teh-Ia Huo*. Surgical resection is better than transarterial chemoembolization for hepatocellular carcinoma beyond the Milan criteria independent of performance status. *J Gastrointest Surg* 2014;18:1623-31.
 35. Po-Hong Liu, Yun-Hsuan Lee, Chia-Yang Hsu, Yi-Hsiang Huang, Yi-You Chiou, Han-Chieh Lin, Teh-Ia Huo*. Survival advantage of radiofrequency ablation over transarterial chemoembolization for patients with hepatocellular carcinoma and good performance status within Milan criteria. *Ann Surg Oncol* 2014;21:3835-43.
 36. Po-Hong Liu, Chia-Yang Hsu, Yun-Hsuan Lee, Cheng-Yuan Hsia, Yi-Hsiang Huang, Chien-Wei Su, Yi-You Chiou, Han-Chieh Lin, Teh-Ia Huo*. Uncompromised treatment efficacy in elderly patients with hepatocellular carcinoma: A propensity score analysis. *Medicine* 2014;93:e264.
 37. Chuan-Fu Chen, Po-Hong Liu, Yun-Hsuan Lee, Ya-Ju Tsai, Chia-Yang Hsu, Yi-Hsiang Huang, Yi-You Chiou, Teh-Ia Huo*. Impact of renal insufficiency on patients with hepatocellular carcinoma undergoing radiofrequency ablation. *J Gastroenterol Hepatol* 2015;30:192-8.
 38. Po-Hong Liu, Cheng-Yuan Hsia, Yun-Hsuan Lee, Chia-Yang Hsu, Yi-Hsiang Huang, Chien-Wei Su, Rheun-Chuan Lee, Han-Chieh Lin, Teh-Ia Huo*. Surgical resection versus transarterial chemoembolization for BCLC stage C hepatocellular carcinoma. *J*

- Surg Oncol 2015;111:404-9.
39. Yun-Hsuan Lee, Chia-Yang Hsu, Chen-Wei Chu, Po-Hong Liu, Cheng-Yuan Hsia, Yi-Hsiang Huang, Chien-Wei Su, Yi-You Chiou, Han-Chieh Lin, Teh-Ia Huo*. Radiofrequency ablation is better than surgical resection in patients with small hepatocellular carcinoma and preserved liver function. J Clin Gastroenterol 2015;49:242-9.
 40. Chia-Yang Hsu, Po-Hong Liu, Yun-Hsuan Lee, Cheng-Yuan Hsia, Yi-Hsiang Huang, Yi-You Chiou, Ya-Ju Tsai, Teddy S. Nagaria, Teh-Ia Huo*. Aggressive therapeutic strategies improve survival of hepatocellular carcinoma patients with performance status 1 or 2: A propensity score analysis. Ann Surg Oncol 2015;22:1324-31.
 41. Chia-Yang Hsu, Po-Hong Liu, Yun-Hsuan Lee, Cheng-Yuan Hsia, Yi-Hsiang Huang, Yi-You Chiou, Han-Chieh Lin, Teh-Ia Huo*. Hepatocellular carcinoma patients with performance status 1 deserve new classification and treatment algorithm in the BCLC system. Medicine 2015;94:e1223.
 42. Chia-Yang Hsu, Po-Hong Liu, Yun-Hsuan Lee, Cheng-Yuan Hsia, Yi-Hsiang Huang, Han-Chieh Lin, Yi-You Chiou, Fa-Yauh Lee, Teh-Ia Huo*. Using serum α -fetoprotein for prognostic prediction in patients with hepatocellular carcinoma: What is the most optimal cutoff? PLoS ONE 2015;10:e0118825.
 43. Po-Hong Liu, Chia-Yang Hsu, Yun-Hsuan Lee, Chien-Wei Su, Cheng-Yuan Hsia, Yi-Hsiang Huang, Yi-You Chiou, Han-Chieh Lin, Teh-Ia Huo*. Hong Kong Liver Cancer staging system is associated with better performance for hepatocellular carcinoma: Special emphasis on viral etiology. Medicine 2015;94:e1772.
 44. Chia-Yang Hsu, Po-Hong Liu, Yun-Hsuan Lee, Cheng-Yuan Hsia, Yi-Hsiang Huang, Ya-Ju Tsai, Teddy S. Nagaria, Han-Chieh Lin, Teh-Ia Huo*. Active treatments prolong the survival in patients with hepatocellular carcinoma and performance status 3 or 4: A propensity score analysis. J Clin Gastroenterol 2015;49:878-884.
 45. Po-Hong Liu, Chia-Yang Hsu, Yun-Hsuan Lee, Cheng-Yuan Hsia, Yi-Hsiang Huang, Chien-Wei Su, Yi-You Chiou, Han-Chieh Lin, Teh-Ia Huo*. When to perform surgical resection or radiofrequency ablation for early hepatocellular carcinoma? A nomogram-guided treatment strategy. Medicine 2015;94:e1929.

46. Po-Hong Liu, Teh-Ia Huo*. Surgery for advanced hepatocellular carcinoma: Time to take action. *J Surg Oncol* 2015;112:909.
47. Po-Hong Liu, Chia-Yang Hsu, Cheng-Yuan Hsia, Yun-Hsuan Lee, Chien-Wei Su, Yi-Hsiang Huang, Fa-Yauh Lee, Han-Chieh Lin, Teh-Ia Huo*. Prognosis of hepatocellular carcinoma: Assessment of eleven staging systems. *J Hepatol* 2016;64:601-608. (*with an editorial*)
48. Chia-Yang Hsu, Po-Hong Liu, Cheng-Yuan Hsia, Yun-Hsuan Lee, Teddy S. Nagaria, Rheun-Chuan Lee, Han-Chieh Lin, Teh-Ia Huo*. Surgical resection is better than transarterial chemoembolization for patients with hepatocellular carcinoma beyond the Milan criteria: A prognostic nomogram study. *Ann Surg Oncol* 2016;23:994-1002.
49. Po-Hong Liu, Chia-Yang Hsu, Cheng-Yuan Hsia, Yun-Hsuan Lee, Yi-Hsiang Huang, Yi-You Chiou, Han-Chieh Lin, Teh-Ia Huo*. Surgical resection versus radiofrequency ablation for single hepatocellular carcinoma ≤ 2 cm in a propensity score model. *Ann Surg* 2016; 263:538-545.
50. Po-Hong Liu, Teh-Ia Huo*. Reply to “Hepatocellular carcinoma scoring and staging systems: Do we need new tools?” *J Hepatol* 2016;64:1450-1452.
51. Po-Hong Liu, Chien-Wei Su, Chia-Yang Hsu, Yun-Hsuan Lee, Cheng-Yuan Hsia, Yi-Hsiang Huang, Rheun-Chuan Lee, Han-Chieh Lin, Teh-Ia Huo*. Solitary large hepatocellular carcinoma: Staging and treatment strategy. *PLoS One* 2016;11: e0155588.
52. Po-Hong Liu, Chia-Yang Hsu, Cheng-Yuan Hsia, Yun-Hsuan Lee, Yi-Hsiang Huang, Chien-Wei Su, Fa-Yauh Lee, Han-Chieh Lin, Teh-Ia Huo*. Proposal and validation of a new model to estimate survival for hepatocellular carcinoma patients. *Eur J Cancer* 2016;63:25-33.
53. Chia-Yang Hsu, Po-Hong Liu, Cheng-Yuan Hsia, Yun-Hsuan Lee, Alhareth Al Juboori, Rheun-Chuan Lee, Han-Chieh Lin, Teh-Ia Huo*. Nomogram of the Barcelona Clinic Liver Cancer system for individual prognostic prediction in hepatocellular carcinoma. *Liver Int* 2016;36:1498-1506.
54. Chia-Yang Hsu, Teh-Ia Huo*. Nomogram of the Barcelona Clinic Liver Cancer system: on the go. *Liver Int* 2016;36:1717-1718.

55. Po-Hong Liu, Teh-Ia Huo*. Utility of prognostic scoring systems in management of hepatocellular carcinoma. *Eur J Cancer* 2016;68:206-207.
56. Yu-Wen Su, Po-Hong Liu, Chia-Yang Hsu, Yun-Hsuan Lee, Cheng-Yuan Hsia, Shu-Yein Ho, Ming-Chih Hou, Harn-Shen Chen, Teh-Ia Huo*. Prognostic impact of diabetes mellitus on hepatocellular carcinoma: Special emphasis from the BCLC perspective. *PLoS One* 2017;12:e0174333.
57. Po-Hong Liu, Chia-Yang Hsu, Cheng-Yuan Hsia, Yun-Hsuan Lee, Yi-You Chiou, MD, Yi-Hsiang Huang, Fa-Yauh Lee, Han-Chieh Lin, Ming-Chih Hou, Teh-Ia Huo*. ALBI and PALBI grade predict survival for hepatocellular carcinoma across treatment modalities and BCLC stages in the MELD era. *J Gastroenterol Hepatol* 2017;32:879-886.
58. Shu-Yein Ho, Po-Hong Liu, Chia-Yang Hsu, Cheng-Yuan Hsia, Yun-Hsuan Lee, Rheun-Chuan Lee, Yi-Hsiang Huang, Fa-Yauh Lee, Ming-Chih Hou, Ya-Ju Tsai, Teh-Ia Huo*. Prognostic role of noninvasive liver reserve markers in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. *PLoS One* 2017;12:e0180408.
59. Po-Hong Liu, Teh-Ia Huo*. Treating very early-stage HCC: Have we found the Holy Grail? *Ann Surg* 2017;266:e31-e32.
60. Chia-Yang Hsu, Po-Hong Liu, Cheng-Yuan Hsia, Yun-Hsuan Lee, Teddy S. Nagaria, Rheun-Chuan Lee, Shu-Yein Ho, Ming-Chih Hou, Teh-Ia Huo*. A new treatment-integrated prognostic nomogram of the Barcelona Clinic Liver Cancer system for hepatocellular carcinoma. *Sci Rep* 2017;7:7914.
61. Teh-Ia Huo*, Po-Hong Liu, Chia-Yang Hsu. ALBI score as a novel tool in staging and treatment planning for hepatocellular carcinoma: Is it sufficient? *Liver Cancer* 2017;6:375-376.
62. Chia-Yang Hsu, Po-Hong Liu, Shu-Yein Ho, Yi-Hsiang Huang, Yun-Hsuan Lee, Yi-You Chiou, Ting-Hui Hsieh, Tom Fang, Ya-Ju Tsai, Ming-Chih Hou, Teh-Ia Huo*. Impact of tumor burden on prognostic prediction for patients with terminal stage hepatocellular carcinoma: A nomogram study. *PLoS One* 2017;12:e0188031.

63. Teh-Ia Huo*, Po-Hong Liu, Chia-Yang Hsu. Comment on 'Transarterial chemo-embolisation of hepatocellular carcinoma: Impact of liver function and vascular invasion'. Br J Cancer 2017;117:e5.
64. Teh-Ia Huo*, Chia-Yang Hsu, Po-Hong Liu. Performance status in patients with HCC: New kid on the block. J Hepatol 2017;67:1352-1353.
65. Po-Hong Liu, Teh-Ia Huo*. Ablation for hepatocellular carcinoma: Where do we stand? Ann Surg 2017;266:e55-e56.
66. Shu-Yein Ho, Po-Hong Liu, Chia-Yang Hsu, Yi-You Chiou, Chien-Wei Su, Yun-Hsuan Lee, Yi-Hsiang Huang, Fa-Yauh Lee, Ming-Chih Hou, Teh-Ia Huo*. Prognostic performance of ten liver function models in patients with hepatocellular carcinoma undergoing radiofrequency ablation. Sci Rep 2018;8:843.
67. Chia-Yang Hsu, Po-Hong Liu, Shu-Yein Ho, Cheng-Yuan Hsia, Praneeth Kudaravalli, Yun-Hsuan Lee, Yi-You Chiou, Ya-Ju Tsai, Yi-Hsiang Huang, Teh-Ia Huo*. Using nomogram of the Barcelona Clinic Liver Cancer system for treatment selection in patients with stage C hepatocellular carcinoma. BMC Cancer 2018;18:289.
68. Teh-Ia Huo*, Po-Hong Liu, Chia-Yang Hsu. Detecting microvascular invasion in HCC with contrast-enhanced MRI: Is it a good idea? J Hepatol 2018;68:862-863.
69. Shu-Yein Ho, Po-Hong Liu, Chia-Yang Hsu, Cheng-Yuan Hsia, Chien-Wei Su, Yun-Hsuan Lee, Yi-Hsiang Huang, Fa-Yauh Lee, Ming-Chih Hou, Teh-Ia Huo*. Comparison of twelve liver functional reserve models for outcome prediction in patients with hepatocellular carcinoma undergoing surgical resection. Sci Rep 2018;8:4773.
70. Teh-Ia Huo*, Chia-Yang Hsu, Po-Hong Liu. Magic mirror on the wall: Which is the best biomarker for hepatocellular carcinoma? Hepatology 2018;67:2482-2483.
71. Chia-Yang Hsu, Po-Hong Liu, Shu-Yein Ho, Yi-Hsiang Huang, Yun-Hsuan Lee, Rheun-Chuan Lee, Teddy S. Nagaria, Ming-Chih Hou, Teh-Ia Huo*. Metastasis in patients with hepatocellular carcinoma: Prevalence, determinants, prognostic impact and ability to improve the BCLC system. Liver Int 2018;38:1803-1811.
72. Shu-Yein Ho, Po-Hong Liu, Chia-Yang Hsu, Cheng-Yuan Hsia, Chien-Wei Su, Yi-Jhen He, Yun-Hsuan Lee, Yi-Hsiang Huang, Ming-Chih Hou, Teh-Ia Huo*.

- Current noninvasive liver reserve models do not predict histological fibrosis severity in hepatocellular carcinoma. *Sci Rep* 2018;8:15074.
73. Yun-Cheng Hsieh, Kuei-Chuan Lee, Ying-Wen Wang, Ying-Ying Yang, Ming-Chih Hou, Teh-Ia Huo*, Han-Chieh Lin*. Correlation and prognostic accuracy between noninvasive liver fibrosis markers and portal pressure in cirrhosis: Role of ALBI score. *PLoS One* 2018;13: e0208903.
 74. Teh-Ia Huo*, Po-Hong Liu, Chia-Yang Hsu. Staging and restaging for hepatocellular carcinoma: Solution of confusion? *Hepatology* 2019;69:464-5.
 75. Teh-Ia Huo*. ALBI grade as a new player in hepatocellular carcinoma. *J Chin Med Asso* 2019;82:1.
 76. Teh-Ia Huo*, Po-Hong Liu, Chia-Yang Hsu. Predicting post-resection recurrence of hepatocellular carcinoma: Spleen stiffness vs ALBI grade. *J Hepatol* 2019;70:808.
 77. Shu-Yein Ho, Chia-Yang Hsu, Po-Hong Liu, Cheng-Yuan Hsia, Chien-Wei Su, Yi-Hsiang Huang, Ming-Chih Hou, Teh-Ia Huo*. Albumin-bilirubin (ALBI) grade-based nomogram to predict tumor recurrence in patients with hepatocellular carcinoma. *Eur J Surg Oncol* 2019;45:776-781.
 78. Shu-Yein Ho, Po-Hong Liu, Chia-Yang Hsu, Cheng-Yuan Hsia, Chien-Wei Su, Yi-Hsiang Huang, Hao-Jan Lei, Yi-Jhen He, Ming-Chih Hou, Teh-Ia Huo*. An albumin-bilirubin (ALBI) grade-based prognostic model for patients with hepatocellular carcinoma within Milan criteria. *Am J Clin Oncol* 2019;42:698-704.
 79. Ping-Hsing Tsai, Yueh Chien, Mong-Lien Wang, Chih-Hung Hsu, Benoit Laurent, Shih-Jie Chou, Wei-Chao Chang, Chian-Shiu Chien, Hsin-Yang Li, Hsin-Chen Lee, Teh-Ia Huo (co-first author), Jui-Hung Hung, Chung-Hsuan Chen, Shih-Hwa Chiou. Ash2l interacts with Oct4-stemness circuitry to promote super-enhancer-driven pluripotency network. *Nucleic Acids Res* 2019; 47:10115-10133.
 80. Shu-Yein Ho, Chia-Yang Hsu, Po-Hong Liu, Cheng-Yuan Hsia, Hao-Jan Lei, Yi-Hsiang Huang, Chih-Chieh Ko, Chien-Wei Su, Rheun-Chuan Lee, Ming-Chih Hou, Teh-Ia Huo*. Albumin-bilirubin grade-based nomogram of the BCLC system for personalized prognostic prediction in hepatocellular carcinoma. *Liver Int* 2020;40:205-214.

81. Teh-Ia Huo*, Shu-Yein Ho. Evolution of hepatocellular carcinoma: Non-B, non-C and beyond. *J Gastroenterol* 2020;55:123-124.
82. Shu-Yein Ho, Po-Hong Liu, Chia-Yang Hsu, Cheng-Yuan Hsia, Yi-Hsiang Huang, Chien-Wei Su, Hao-Jan Lei, Rheun-Chuan Lee, Ming-Chih Hou, Teh-Ia Huo*. A new prognostic model based on albumin-bilirubin grade for hepatocellular carcinoma beyond the Milan criteria. *Dig Dis Sci* 2020;65:658-667.
83. Teh-Ia Huo*, Po-Hong Liu. Too many vs too few platelets in patients with hepatocellular carcinoma: Good or bad? *Liver Cancer* 2020;9:108-109.
84. Shu-Yein Ho, Po-Hong Liu, Chia-Yang Hsu, Cheng-Yuan Hsia, Yi-Hsiang Huang, Hao-Jan Lei, Chien-Wei Su, Rheun-Chuan Lee, Ming-Chih Hou, Teh-Ia Huo*. Evolution of etiology, presentation, management and prognostic tool in hepatocellular carcinoma. *Sci Rep* 2020;10:3925.
85. Teh-Ia Huo*, Po-Hong Liu, Chia-Yang Hsu. Nomogram to predict surgical hepatocellular carcinoma with Child-Pugh B: Feasibility and overlooked predictors. *J Hepatol* 2020;72:1032-1033.
86. Shu-Yein Ho, Chia-Yang Hsu, Po-Hong Liu, Chih-Chieh Ko, Yi-Hsiang Huang, Chien-Wei Su, Rheun-Chuan Lee, Ming-Chih Hou, Teh-Ia Huo*. Survival of patients with hepatocellular carcinoma in renal insufficiency: Prognostic role of albumin-bilirubin grade. *Cancers* 2020;12:1130.
87. Teh-Ia Huo*, Po-Hong Liu, Shu-Yein Ho. Are inflammation-based models feasible tools in predicting the outcome of patients with hepatocellular carcinoma? *Liver Int* 2020; 40:1498.
88. I-Cheng Lee, Teh-Ia Huo*, Yi-Hsiang Huang*. Gastrointestinal and liver manifestations in patients with COVID-19. *J Chin Med Asso* 2020;83:521-523.
89. Shu-Yein Ho, Lei-Chi Wang, Chia-Yang Hsu, Po-Hong Liu, Cheng-Yuan Hsia, Yi-Hsiang Huang, Teh-Ia Huo*. Metavir fibrosis stage in hepatitis C-related hepatocellular carcinoma and association with noninvasive liver reserve models. *J Gastrointest Surg* 2020;24:1860-1862.
90. Po-Hong Liu, Chia-Yang Hsu, Chien-Wei Su, Yi-Hsiang Huang, Ming-Chih Hou, Nicole E. Rich, Naoto Fujiwara, Yujin Hoshida, Amit Singal*, Teh-Ia Huo*.

Thrombocytosis is associated with worse survival in patients with hepatocellular carcinoma. *Liver Int* 2020;40:2522-2534.

91. Teh-Ia Huo*, Shu-Yein Ho, Chih-Chieh Ko. Stereotactic body radiation therapy vs. radiofrequency ablation for HCC: More questions than answers. *J Hepatol* 2020;73:972-973.
92. Shu-Yein Ho, Mei-Hsia Yuan, Chu-Chieh Chen, Po-Hong Liu, Chia-Yang Hsu, Yi-Hsiang Huang, Hao-Jan Lei, Rheun-Chuan Lee, Teh-Ia Huo*. Differential survival impact of diabetes mellitus on hepatocellular carcinoma: Role of staging determinants. *Dig Dis Sci* 2020;65:3389-3402.
93. Teh-Ia Huo*, Po-Hong Liu, Chia-Yang Hsu. Tumor burden score for hepatocellular carcinoma: Is it an authentic prognostic marker? *Br J Surg* 2020;107:e625.
94. Teh-Ia Huo*, Po-Hong Liu, Shu-Yein Ho. Treating small hepatocellular carcinoma: Stereotactic body radiation therapy vs radiofrequency ablation. *J Gastroenterol Hepatol* 2020;35:2020.
95. Yi-Ying Lin, Yi-Ping Yang, Wei-Yi Lai, Chian-Shiu Chien, Shih-Jen Chen, De-Kuang Hwang, Ying-Hsiu Lai, Tai-Chi Lin, Shih-Hwa Chiou, Yu-Li Lo, Teh-Ia Huo*, Yueh Chien*. Development of polydimethylsiloxane-based biomimetic scaffolds with cylinder micropillars for retinal pigment epithelial cell cultivation. *J Chin Med Asso* 2020;83:1029-1033.
96. Teh-Ia Huo*, Shu-Yein Ho, Po-Hong Liu. Is computed tomography-enhanced clinical significant portal hypertension surrogate an authentic prognostic predictor for surgical hepatocellular carcinoma? *J Gastroenterol Hepatol* 2020;35:2289.

Co-authorship:

97. Hsu CY, Lee FY, Huo TI, Chan CY, Huang HC, Lin HC, Chang CC, Teng TH, Wang SS, Lee SD. Lack of therapeutic effects of gabexate mesilate on hepatic encephalopathy in rats with acute or chronic hepatic failure. *J Gastroenterol Hepatol* 2010;25:1325-8.
98. Huang YH, Hung HH, Chan CC, Lai CR, Chu CJ, Huo TI, Lee PC, Su CW, Lan KH, Huang HC, Lee IC, Lin HC, Lee SD. Core antigen expression is associated with

- hepatic necroinflammation in e antigen-negative chronic hepatitis B patients with low DNA loads. *Clin Vaccine Immunol* 2010;17:1048-53.
99. Lee IC, Huang YH, Chan CC, Huo TI, Chu CJ, Lai CR, Lee PC, Su CW, Hung HH, Wu JC, Lin HC, Lee SD. Correlation between clinical indication for treatment and liver histology in HBeAg-negative chronic hepatitis B: A novel role of alpha-fetoprotein. *Liver Int* 2010;30:1161-8.
100. Hung HH, Su CW, Lai CR, Chau GY, Chan CC, Huang YH, Huo TI, Lee PC, Kao WY, Lee SD, Wu JC. Fibrosis and AST to platelet ratio index predict post-operative prognosis for solitary small hepatitis-B related hepatocellular carcinoma. *Hepatol Int* 2010;4:691-9.
101. Hung HH, Chiou YY, Hsia CY, Su CW, Chou YH, Chiang JH, Kao WY, Huo TI, Huang YS, Su YH, Lin HC, Lee SD, Wu JC. Survival rates are comparable following radiofrequency ablation or surgery in patients with small hepatocellular carcinomas. *Clin Gastroenterol Hepatol* 2011;9:79-86.
102. Kao WY, Chiou YY, Hung HH, Chou YH, Su CW, Wu JC, Huo TI, Huang YH, Lin HC, Lee SD. Risk factors for long-term prognosis in hepatocellular carcinoma after radiofrequency ablation therapy: The clinical implication of aspartate aminotransferase-platelet ratio index. *Eur J Gastroenterol Hepatol* 2011;23:528-36.
103. Lee IC, Huang YH, Chan CC, Huo TI, Chu CJ, Lai CR, Lee PC, Su CW, Wu JC, Lin HC, Lee SD. Impact of body mass index and viral load on liver histology in hepatitis B e antigen-negative chronic hepatitis B. *Clin Nutr* 2011;30:647-52.
104. Lee JY, Huo TI, Huang HC, Lee FY, Lin HC, Chuang CL, Chang CC, Wang SS, Lee SD. Propranolol modulates the collateral vascular responsiveness to vasopressin via $G\alpha$ -mediated pathway in portal hypertensive rats. *Clin Sci* 2011;121:545-54.
105. Kao WY, Chiou YY, Hung HH, Su CW, Chou YH, Huo TI, Huang YH, Wu WC, Lin HC, Lee SD, Wu JC. Younger hepatocellular carcinoma patients have better prognosis after percutaneous radiofrequency ablation therapy. *J Clin Gastroenterol* 2012;46:62-70.
106. Kao WY, Chiou YY, Hung HH, Su CW, Chou YH, Wu JC, Huo TI, Huang YH, Wu WC, Lin HC, Lee SD. Serum alpha-fetoprotein response can predict prognosis in

- hepatocellular carcinoma patients undergoing radiofrequency ablation therapy. *Clin Radiol* 2012;67:429-36.
107. Hsu C, Yang TS, Huo TI, Hsieh RK, Yu CW, Hwang WS, Hsieh TY, Huang WT, Chao Y, Meng R, Cheng AL. Vandetanib in patients with inoperable hepatocellular carcinoma: a phase II, randomized, double-blind, placebo-controlled study. *J Hepatol* 2012;56:1097-103.
108. Wu WC, Chiou YY, Hung HH, Kao WY, Chou YH, Su CW, Wu JC, Huo TI, Huang YH, Lee KC, Lin HC, Lee SD. Prognostic significance of computed tomography scan-derived splenic volume in hepatocellular carcinoma treated with radiofrequency ablation. *J Clin Gastroenterol* 2012;46:789-95.
109. Hsieh YC, Chen CK, Su CW, Chan CC, Huo TI, Liu CJ, Fang WL, Lee KC, Lin HC. Outcome after percutaneous cholecystostomy for acute cholecystitis: A single-center experience. *J Gastrointest Surg* 2012;16:1860-8.
110. Luo JC, Huo TI, Hou MC, Lin HY, Li CP, Lin HC, Chang FY, Lee FY. Clopidogrel delays gastric ulcer healing in rats. *Eur J Pharmacol* 2012;695:112-9.
111. Chan CC, Cheng LY, Lu J, Huang YH, Chiou SH, Tsai PH, Huo TI, Lin HC, Lee FY. The role of interferon- γ inducible protein-10 in a mouse model of acute liver injury post induced pluripotent stem cells transplantation. *PLoS One* 2012;7:e50577.
112. Chen PH, Kao WY, Chiou YY, Hung HH, Su CW, Chou YH, Huo TI, Huang YH, Wu WC, Chao Y, Lin HC, Wu JC. Comparison of prognosis by viral etiology in patients with hepatocellular carcinoma after radiofrequency ablation. *Ann Hepatol* 2013;12:263-73.
113. Lee IC, Lin CH, Huang YH, Huo TI, Su CW, Hou MC, Huang HC, Lee KC, Chan CC, Lin MW, Lin HC, Lee SD. IL28B polymorphism correlates with active hepatitis in patients with HBeAg-negative chronic hepatitis B. *PLoS One* 2013;8:e58071.
114. Yang YY, Lee FY, Hsu HC, Lee WS, Chuang CL, Chang CC, Huo TI, Huang YH, Huang CC, Huang CC. Validation of the behavior and concept based assessment of professionalism competence in postgraduate first-year residents. *J Chin Med Assoc* 2013;76:186-94.
115. Su CW, Chiou YW, Tsai YH, Teng RD, Chau GY, Lei HJ, Hung HH, Huo TI, Wu JC.

- The influence of hepatitis B viral load and pre-S deletion mutations on post-operative recurrence of hepatocellular carcinoma and the tertiary preventive effects by anti-viral therapy. *PLoS One* 2013;8:e66457.
116. Lee JY, Huo TI, Wang SS, Huang HC, Lee FY, Lin HC, Chuang CL, Lee SD. Diabetes diminishes the portal-systemic collateral vascular response to vasopressin via vasopressin receptor and $G\alpha$ proteins regulations in cirrhotic rats. *PLoS One* 2013;8:e67703.
117. Cheng YL, Wang YJ, Kao WY, Chen PH, Huo TI, Huang YH, Lan KH, Su CW, Chan WL, Lin HC, Lee FY, Wu JC. Inverse association between hepatitis B virus infection and fatty liver disease: A large-scale study in populations seeking for check-up. *PLoS ONE* 2013;8:e72049.
118. Lee IC, Huang YH, Su CW, Wang YJ, Huo TI. CXCL9 associated with sustained virological response in chronic hepatitis B patients receiving peginterferon alfa-2a therapy: A pilot study. *PLoS ONE* 2013;8:e76798.
119. Lee IC, Huang YH, Chau GY, Huo TI, Su CW, Wu JC, Lin HC. Serum interferon gamma level predicts recurrence in hepatocellular carcinoma patients after curative treatments. *Int J Cancer* 2013;133:2895-902.
120. Chiang CH, Huo TI, Sun CC, Hsieh JH, Chien Y, Lu KH, Lee SD. Induced pluripotent stem cells and hepatic differentiation. *J Chin Med Assoc* 2013;76:599-605.
121. Chao J, Huo TI, Cheng HY, Tsai JC, Liao JW, Lee MS, Qin XM, Hsieh MT, Pao LH, Peng WH. Gallic acid ameliorated impaired glucose and lipid homeostasis in high fat diet-induced NAFLD mice. *PLoS One* 2014;9:e96969.
122. Hsu SJ, Wang SS, Hsin IF, Lee FY, Huang HC, Huo TI, Lee WS, Lin HC, Lee SD. Green tea polyphenol decreases the severity of portosystemic collaterals and mesenteric angiogenesis in rats with liver cirrhosis. *Clin Sci* 2014;126:633-44.
123. Ho JK, Huo TI, Lin LC, Tsai TH. Pharmacokinetics of ractopamine and its organ distribution 1 in rats. *J Agric Food Chem* 2014;62:9273-8.
124. Hung HH, Chao Y, Chiou YY, Li CP, Lee RC, Huo TI, Huang YH, Chau GY, Su CW, Yeh YC, Lin HC, Lee SD, Wu JC. A comparison of clinical manifestations and prognoses between patients with hepatocellular carcinoma and Child-Pugh scores of 5

- or 6. *Medicine* 2014;93:e348.
125. Cheng YL, Wang YC, Lan KH, Huo TI, Huang YH, Su CW, Lin HC, Lee FY, Wu JC, Lee SD. Anti-hepatitis C virus seropositivity is not associated with metabolic syndrome irrespective of age, gender and fibrosis. *Ann Hepatol* 2015;14:181-9.
126. Lee JY, Huo TI, Wang SS, Huang HC, Lee FY, Lin HC, Chuang CL, Lee SD. Diabetes enhances the intrahepatic vascular response to endothelin-1 in cirrhotic rats: association with the ETA receptor and pERK up-regulation. *Liver Int* 2015;35:704-12.
127. Hsieh YC, Lee KC, Yang YY, Huo TI, Huang YH, Lin HC. Interleukin-1 receptor antagonist correlates with hepatic venous pressure gradient and predicts occurrence of overall complications and bacterial infections in patients with cirrhosis. *Hepatol Res* 2015;45:294-304.
128. Yang BL, Wu WC, Fang KC, Wang YC, Huo TI, Huang YH, Yang HI, Su CW, Lin HC, Lee FY, Wu JC, Lee SD. External validation of fatty liver index for identifying ultrasonographic fatty liver in a large-scale cross-sectional study in Taiwan. *PLoS One* 2015;10:e0120443.
129. Tung HC, Lee FY, Wang SS, Tsai MH, Lee JY, Huo TI, Huang HC, Chuang CL, Lin HC, Lee SD. The beneficial effects of P2X7 antagonism in rats with bile duct ligation-induced cirrhosis. *PLoS One* 2015;10:e0124654.
130. Lee IC, Chen YT, Chao Y, Huo TI, Li CP, Su CW, Lin HC, Lee FY, Huang YH. Determinants of survival after sorafenib failure in patients with BCLC-C hepatocellular carcinoma in real-world practice. *Medicine* 2015;94:e688.
131. Chien Y, Chang YL, Li HY, Larsson M, Wu WW, Chien CS, Wang CY, Chu PY, Chen KH, Lo WL, Chiou SH, Lan YT, Huo TI, Lee SD, Huang PI. Synergetic effects of carboxymethyl-hexanoyl chitosan and cationic polyurethane-short branch PEI in miR122 gene delivery: Accelerated differentiation of iPSCs into mature hepatocyte-like cells and improved stem cell therapy in a hepatic failure model. *Acta Biomater* 2015;13:228-44.
132. Chiang CH, Wu WW, Li HY, Chien Y, Sun CC, Peng CH, Lin AT, Huang CS, Lai YH, Chiou SH, Hung SI, Chang YL, Lan YT, Chien CS, Huo TI, Lee SD, Wang CY. Enhanced antioxidant capacity of dental pulp-derived iPSC-differentiated hepatocytes

- and liver regeneration by injectable HGF-releasing hydrogel in fulminant hepatic failure. *Cell Transplant* 2015; 24:541-59.
133. Vitale A, Huo TI, Cucchetti A, Lee YH, Volk M, Frigo AC, Cescon M, Tuci F, Pinna AD, Cillo U. The survival benefit of liver transplantation versus resection for hepatocellular carcinoma: impact of MELD score. *Ann Surg Oncol* 2015;22:1901-7.
134. Hsu SJ, Wang SS, Huo TI, Lee FY, Huang HC, Chang CC, Hsin IF, Ho HL, Lin HC, Lee SD. The impacts of spironolactone on severity of portal-systemic collaterals and hepatic encephalopathy in cirrhotic rats. *J Pharmacol Exp Ther* 2015; 355:117-24.
135. Kao WY, Chao Y, Chang CC, Li CP, Su CW, Huo TI, Huang YH, Chang YJ, Lin HC, Wu JC. Prognosis of early-stage hepatocellular carcinoma: the clinical implications of substages of Barcelona Clinic Liver Cancer System based on a cohort of 1265 patients. *Medicine* 2015;94:e1929.
136. Farinati F, Vitale A, Spolverato G, Pawlik TM, Huo TI, Lee YH, Frigo AC, Giacomini A, Giannini EG, Ciccarese F, Piscaglia F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Borzio F, Cabibbo G, Felder M, Sacco R, Morisco F, Biasini E, Foschi FG, Gasbarrini A, Svegliati Baroni G, Virdone R, Masotto A, Trevisani F, Cillo U; ITA.LI.CA study group. Development and validation of a new prognostic system for patients with hepatocellular carcinoma. *PLoS Med* 2016;13:e1002006.
137. Hsin IF, Lee JY, Huo TI, Lee FY, Huang HC, Hsu SJ, Wang SS, Ho HL, Lin HC, Lee SD. 2'-hydroxyflavanone ameliorates mesenteric angiogenesis and portal-systemic collaterals in rats with liver fibrosis. *J Gastroenterol Hepatol* 2016;31:1045-51.
138. Luo JC, Peng YL, Chen TS, Huo TI, Hou MC, Huang HC, Lin HC, Lee FY. Clopidogrel inhibits angiogenesis of gastric ulcer healing via downregulation of vascular endothelial growth factor receptor 2. *J Formos Med Assoc* 2016;115:764-72.
139. Lee PC, Yeh CM, Hu YW, Chen CC, Liu CJ, Su CW, Huo TI, Huang YH, Chao Y, Chen TJ, Lin HC, Wu JC. Antiplatelet therapy is associated with a better prognosis in patients with hepatitis B virus-related hepatocellular carcinoma after liver resection. *Ann Surg Oncol* 2016;23 (Suppl 5):874-883.
140. Wang YC, Yang SS, Su CW, Wang YJ, Lee KC, Huo TI, Lin HC, Huang YH. Predictors of response to pegylated interferon in chronic hepatitis B: a real-world

- hospital-based analysis. *Sci Rep* 2016;6:29605.
141. Tung HC, Hsu SJ, Tsai MH, Lin TY, Hsin IF, Huo TI, Lee FY, Huang HC, Ho HL, Lin HC, Lee SD. Homocysteine deteriorates intrahepatic derangement and portal-systemic collaterals in cirrhotic rats. *Clin Sci* 2017;131:69-86.
142. Fang KC, Su CW, Chiou YY, Lee PC, Chiu NC, Liu CA, Chen PH, Kao WY, Huang YH, Huo TI, Hou MC, Lin HC, Wu JC. The impact of clinically significant portal hypertension on the prognosis of patients with hepatocellular carcinoma after radiofrequency ablation: a propensity score matching analysis. *Eur Radiol* 2017;27:2600-2609.
143. Hsieh WY, Chen PH, Lin IY, Su CW, Chao Y, Huo TI, Huang YH, Hou MC, Lin HC, Wu JC. The impact of esophagogastric varices on the prognosis of patients with hepatocellular carcinoma. *Sci Rep* 2017;7:42577.
144. Fang KC, Cheng YL, Su CW, Wang YJ, Lan KH, Huo TI, Huang YH, Chu CJ, Lin CC, Hou MC, Lin HC, Lee FY, Wu JC, Lee SD. Higher platelet counts are associated with metabolic syndrome independent of fatty liver diagnosis. *J Chin Med Assoc* 2017;80:125-132.
145. Cheng YL, Wang YJ, Lan KH, Huo TI, Huang YH, Su CW, Hsieh WY, Hou MC, Lin HC, Lee FY, Wu JC, Lee SD. Fatty liver index and lipid accumulation product can predict metabolic syndrome in subjects without fatty liver disease. *Gastroenterol Res Pract* 2017;2017:9279836.
146. Gavriilidis P, Roberts KJ, Askari A, Sutcliffe RP, Huo TI, Liu PH, Hidalgo E, Compagnon P, Lim C, Azoulay D. Evaluation of the current guidelines for resection of hepatocellular carcinoma using the Appraisal of Guidelines for Research and Evaluation II instrument. *J Hepatol* 2017;67:991-998.
147. Ho HL, Huo TI, Chang T, Lee WS, Hsin IF, Lee FY, Huang HC, Hou MC, Lee SD. Ascorbate lacks significant influence in rats with bile duct ligation-induced liver injury. *J Chin Med Assoc* 2017;80:539-550.
148. Kao WY, Su CW, Chiou YY, Chiu NC, Liu CA, Fang KC, Huo TI, Huang YH, Chang CC, Hou MC, Lin HC, Wu JC. Hepatocellular carcinoma: Nomograms based on the albumin-bilirubin grade to assess the outcomes of radiofrequency ablation. *Radiology*

- 2017;285:670-680.
149. Jiang SH, Cheng YY, Huo TI, Tsai TH. Pharmacokinetics of rhodamine 110 and its organ distribution in rats. *J Agr Food Chem* 2017;65:7797-7804.
150. Lee IC, Chau GY, Yeh YC, Chao Y, Huo TI, Su CW, Lin HC, Hou MC, Huang YH. Risk of recurrence in chronic hepatitis B patients developing hepatocellular carcinoma with antiviral secondary prevention failure. *PLoS One* 2017;12: e0188552.
151. Lee PC, Chen YT, Chao Y, Huo TI, Li CP, Su CW, Lee MH, Hou MC, Lee FY, Lin HC, Huang YH. Validation of the ALBI grade-based integrated model as a predictor for sorafenib-failed hepatocellular carcinoma. *Liver Int* 2018;38:321-330.
152. Lu SN, Wang JH, Su CW, Wang TE, Dai CY, Chen CH, Chen RC, Yang SS, Hung CF, Huang SF, Liao LY, Huo TI, Wu CC, Lee PH, Ting CT, Lee WC, Chau GY, Hung CF, Wang CC, Lee KT, Wang JH, Huang YH, Ho MC, Lin SM, Huang GT, Chen KY, Lin XZ, Liao LY, Hwang JI, Chiou YY, Wang CK, Hu JT, Chen SC, Hwang JI, Liang PC, Hung CF, Lee RC, Wu DK, Lin CY, Lin CC, Chen RC, Cheng AL, Hsu C, Huang YH, Chao Y, Chen LT, Wang PM, Wang PM, Hong JH, Hsu HC, Chen SW, Leung SW, Cheng JC, Lin CC, Hung CF, Wu JC, Wu CY, Hsu YC, Hsu CW, Ni YH, Wu CC, Hwang JI, Chen SW, Lin CL. Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan. *J Formos Med Assoc* 2018;117:381-403.
153. Hsin IF, Hsu SJ, Chuang CL, Huo TI, Huang HC, Lee FY, Ho HL, Chang SY, Lee SD. The effects of proton pump inhibitor on hepatic vascular responsiveness and hemodynamics in cirrhotic rats. *J Chin Med Assoc* 2018;81:585-592.
154. Liu PH, Huo TI, Miksad RA. Hepatocellular carcinoma with portal vein tumor involvement: Best management strategies. *Semin Liver Dis* 2018;38:242-251.
155. Lin YY, Chien Y, Chuang JH, Chang CC, Yang YP, Lai YH, Lo WL, Chien KH, Huo TI, Wang CY. Development of a graphene oxide-incorporated polydimethylsiloxane membrane with hexagonal micropillars. *Int J Mol Sci* 2018;19:E2517.
156. Chang CY, Hsieh WY, Chau GY, Chen PH, Su CW, Hou MC, Lei HJ, Huo TI, Huang YH, Lin HC, Wu JC. Esophageal varices are not predictive of patient prognosis after

- surgical resection of hepatocellular carcinoma. *Eur J Gastroenterol Hepatol* 2018;30:1368-1377.
157. Fang KC, Kao WY, Su CW, Chen PC, Lee PC, Huang YH, Huo TI, Chang CC, Hou MC, Lin HC, Wu JC. The prognosis of single large hepatocellular carcinoma was distinct from Barcelona Clinic Liver Cancer stage A or B: The role of albumin-bilirubin grade. *Liver Cancer* 2018;7:335-358.
158. Hsin IF, Huang HC, Chang CC, Hsu SJ, Lee FY, Huo TI, Chuang CL, Hou MC, Lee SD. Insulin reverses the major portal hypertension-related derangements in rats with liver cirrhosis and diabetes. *Clin Sci* 2018;132:2391-2405.
159. Kao WY, Su CW, Tan ECH, Lee PC, Chen PH, Tang JH, Huang YH, Huo TI, Chang CC, Hou MC, Lin HC, Wu JC. Proton pump inhibitors and risk of hepatocellular carcinoma in patients with chronic hepatitis B or C. *Hepatology* 2019;69:1151-1164.
160. Tsai PH, Wang ML, Chang JH, Yarmishyn AA, Nhi Nguyen PN, Chen W, Chien Y, Huo TI, Mou CY, Chiou SH. Dual delivery of HNF4 α and cisplatin by mesoporous silica nanoparticles inhibits cancer pluripotency and tumorigenicity in hepatoma-derived CD133-expressing stem cells. *ACS Appl Mater Interfaces* 2019;11:19808-19818.
161. Ho HL, Tsai MH, Hsieh YH, Huo TI, Chang CC, Lee FY, Huang HC, Hou MC, Lee SD. Folic acid ameliorates homocysteine-induced angiogenesis and portosystemic collaterals in cirrhotic rats. *Ann Hepatol* 2019;18:633-639.
162. Chang T, Ho HL, Hsu SJ, Chang CC, Tsai MH, Huo TI, Huang HC, Lee FY, Hou MC, Lee SD. Glucobrassicin metabolites ameliorate the development of portal hypertension and cirrhosis in bile duct-ligated rats. *Int J Mol Sci* 2019;20:E4161.
163. Lee IC, Hung YW, Liu CA, Lee RC, Su CW, Huo TI, Li CP, Chao Y, Lin HC, Hou MC, Huang YH. A new ALBI-based model to predict survival after transarterial chemoembolization for BCLC stage B hepatocellular carcinoma. *Liver Int* 2019;39:1704-1712.
164. Young SH, Chau GY, Lee IC, Yeh YC, Chao Y, Huo TI, Su CW, Lin HC, Hou MC, Lee MH, Huang YH. Aspirin is associated with low recurrent risk in hepatitis B virus-related hepatocellular carcinoma patients after curative resection. *J Formos Med*

- Assoc 2019;119 (1 Pt 2):218-229.
165. Lee PC, Chiou YY, Chiu NC, Chen PH, Liu CA, Kao WY, Huo TI, Huang YH, Hou MC, Lin HC, Wu JC, Su CW. Liver stiffness measured by acoustic radiation force impulse elastography predicted prognoses of hepatocellular carcinoma after radiofrequency ablation. *Sci Rep* 2020;10:2006.
166. Lee PC, Chen YJ, Chou YC, Lee KC, Chen PH, Kao WY, Huang YH, Huo TI, Lin HC, Hou MC, Lee FY, Wu JC, Su CW. Low dose of propranolol treatment is associated with better survival in cirrhotic patients with hepatic encephalopathy. *Eur J Gastroenterol Hepatol* 2020;32:365-372.
167. Wei CY, Chen PC, Chau GY, Lee RC, Chen PH, Huo TI, Huang YH, Su YH, Hou MC, Wu JC, Su CW. Comparison of prognosis between surgical resection and transarterial chemoembolization for patients with solitary huge hepatocellular carcinoma. *Ann Transl Med* 2020;8:238.
168. Su CW, Fang KC, Lee RC, Liu CA, Chen PH, Lee PC, Kao WY, Huang YH, Huo TI, Hou MC, Lin HC, Wu JC. Association between esophagogastric varices in hepatocellular carcinoma and poor prognosis after transarterial chemoembolization: A propensity score matching analysis. *J Formos Med Assoc* 2020;119:610-620.
169. Wei CY, Chau GY, Chen PH, Liu CA, Huang YH, Huo TI, Hou MC, Lin HC, Su YH, Wu JC, Su CW. A comparison of prognoses between surgical resection and radiofrequency ablation therapy for patients with hepatocellular carcinoma and esophagogastric varices. *Sci Rep* 2020;10:17259.
170. Chen CF, Chien CH, Yang YP, Chou SJ, Wang ML, Huo TI, Lin CC. Role of dipeptidyl peptidase 4 inhibitors in diabetic patients with coronavirus-19 infection. *J Chin Med Assoc* 2020;83:710-711.
171. Chen CF, Chen YT, Chen TH, Chen FY, Yang YP, Wang ML, Huo TI, Chang YL, Tan AC, Lin CC. Judicious use of sodium-glucose cotransporter 2 inhibitors in patients with diabetes on coronavirus-19 pandemic. *J Chin Med Assoc* 2020;83:809-811.